ISP passes on ingredient price hikes to drugmakers

Better alert purchasing because drug ingredient prices are going up, up, up again. All of its biocide products--especially those containing 3-Iodo-Propynyl-Butylcarbamate--are subject to a 10 percent price hike in June, says International Specialty Products of Wayne, NJ. The cost increase comes on top of one made in March.

ISP cites raw material cost escalation, especially for iodine, along with increasing regulatory, compliance, energy and transportation costs as co-conspirators.

Separately, ISP announced a 10 percent across-the-board boost for polymer, vinyl monomer, emollient, emulsifier, preservative and encapsulates prices. This increase follows a 10 percent bump in February. Then as now, material and energy cost escalation is the culprit.

Just two weeks ago, contract manufacturer Lonza cited rising raw material prices as having an impact on its first-half financial performance.

- here's the biocides announcement
- see the polymers release
- see the Lonza story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.